再鼎医药ZL-1109注射液启动Ⅰ期临床 适应症为甲状腺眼病

新浪财经
Oct 29

药物临床试验登记与信息公示平台数据显示,再鼎医药(上海)有限公司的一项在中国健康成人参与者中研究ZL-1109皮下给药制剂的药代动力学、药效学、安全性和耐受性的随机、双盲和安慰剂对照I期研究已启动。临床试验登记号为CTR20254145,首次公示信息日期为2025年10月28日。该药物剂型为注射剂,用法为皮下注射,首次给药600mg,第二次给药300mg。本次试验主要目的为表征ZL-1109重复...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10